Dato-DXd is a TROP2-targeting ADC being investigated in a broad global clinical program across multiple tumor types, including NSCLC, TNBC, and HR-positive, HER2-negative breast cancer. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.